We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
+4.42%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$231M
AUM Growth
-$37.1M
(-14%)
Cap. Flow
-$48M
Cap. Flow
% of AUM
-20.83%
Top 10 Holdings %
Top 10 Hldgs %
50.4%
Holding
85
New
16
Increased
17
Reduced
31
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$7.59M |
| 2 |
Merck
MRK
|
+$5.05M |
| 3 |
TVTY
Tivity Health, Inc. Common Stock
TVTY
|
+$3.65M |
| 4 |
Baxter International
BAX
|
+$3.3M |
| 5 |
IQVIA
IQV
|
+$3.29M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$9.5M |
| 2 |
Becton Dickinson
BDX
|
+$7.34M |
| 3 |
Johnson & Johnson
JNJ
|
+$6.92M |
| 4 |
UnitedHealth
UNH
|
+$6.85M |
| 5 |
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
|
+$6.34M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.59% |
| 2 | Financials | 2.32% |
| 3 | Real Estate | 0.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Thermo Fisher Scientific
TMO
$213B
| $706K | 0.31% |
3,407
-20,401
| -86% | -$4.33M |
|
52
Standard BioTools
LAB
$340M
| $680K | 0.29% |
+114,110
| New | +$650K |
|
|
IMGN
53
DELISTED
Immunogen Inc
IMGN
| $664K | 0.29% |
+68,265
| New | +$720K |
|
54
Viking Therapeutics
VKTX
$3.7B
| $574K | 0.25% |
60,499
-58,601
| -49% | -$390K |
|
|
BLCM
55
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $530K | 0.23% |
7,180
-7,250
| -50% | -$565K |
|
56
Pediatrix Medical
MD
$2.18B
| $409K | 0.18% |
9,442
-64,775
| -87% | -$3.1M |
|
57
Nektar Therapeutics
NKTR
$2.39B
| $386K | 0.17% |
+527
| New | +$608K |
|
|
AKTX
58
Akari Therapeutics
AKTX
$13.8M
| $352K | 0.15% |
225
-22
| -9% | -$34.6K |
|
59
Heron Therapeutics
HRTX
$93.9M
| $343K | 0.15% |
+8,824
| New | +$281K |
|
60
Cencora
COR
$60.6B
| $315K | 0.14% |
+3,692
| New | +$324K |
|
|
CLSD
61
DELISTED
Clearside Biomedical
CLSD
| $314K | 0.14% |
+1,960
| New | +$330K |
|
|
ZGNX
62
DELISTED
Zogenix, Inc.
ZGNX
| $286K | 0.12% |
6,473
-9,827
| -60% | -$405K |
|
63
Labcorp
LH
$25B
| $224K | 0.1% |
1,454
-32,971
| -96% | -$4.98M |
|
64
Ocugen
OCGN
$416M
| $140K | 0.06% |
+936
| New | +$146K |
|
65
AnaptysBio
ANAB
$1.58B
| – | – |
-3,130
| Closed | -$326K |
|
|
AVDL
66
DELISTED
Avadel Pharmaceuticals
AVDL
| – | – |
-55,700
| Closed | -$406K |
|
67
Cardinal Health
CAH
$53.9B
| – | – |
-22,542
| Closed | -$1.41M |
|
68
Quest Diagnostics
DGX
$25.7B
| – | – |
-13,000
| Closed | -$1.3M |
|
69
Danaher
DHR
$137B
| – | – |
-23,987
| Closed | -$2.08M |
|
70
Icon
ICLR
$12.6B
| – | – |
-8,400
| Closed | -$992K |
|
71
Incyte
INCY
$24.2B
| – | – |
-19,420
| Closed | -$1.62M |
|
72
Jazz Pharmaceuticals
JAZZ
$15.9B
| – | – |
-5,100
| Closed | -$770K |
|
|
MASI
73
DELISTED
Masimo
MASI
| – | – |
-20,900
| Closed | -$1.84M |
|
74
VanEck Pharmaceutical ETF
PPH
$959M
| – | – |
-25,500
| Closed | -$1.45M |
|
75
Qiagen
QGEN
$8.54B
| – | – |
-19,333
| Closed | -$662K |
|
Similar funds
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
HSCU
Endurant Capital Management's Q2 2018 Portfolio in Review
As of Q2 2018, Endurant Capital Management held 85 positions worth $231M, down 14% from $268M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Endurant Capital Management withdrew a net $48M in Q2 2018, closing 20 positions and reducing 31 holdings. Its most notable exit was Envision Healthcare Holdings Inc, an estimated $3.16M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Financials and Real Estate.
Against the trend, Endurant Capital Management opened a new position in IQVIA worth $3.29M.
- Endurant Capital Management's largest Q2 2018 buy was IQVIA: 32,945 shares worth $3.29M.
- Endurant Capital Management added most to Cigna in Q2 2018, an estimated $7.59M increase.
- Endurant Capital Management's biggest Q2 2018 reduction was Boston Scientific, cutting an estimated $9.5M.
- Endurant Capital Management fully exited Envision Healthcare Holdings Inc in Q2 2018, selling an estimated $3.16M.
- Endurant Capital Management's ten largest holdings make up 50% of its $231M portfolio in Q2 2018.
- Endurant Capital Management opened 16 new positions and closed 20 in Q2 2018.
- Endurant Capital Management's portfolio value fell 14% quarter-over-quarter to $231M.
Based on Endurant Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.